News

Mindera Health Partners with MultiPlan for Expanded Access

Mindera Health Partners with MultiPlan for Expanded Access

Mindera Health's Strategic Collaboration with MultiPlan

In an exciting development for precision medicine, Mindera Health has entered into a significant partnership with MultiPlan. This collaboration aims to improve access to essential healthcare services, particularly for psoriasis patients who can now benefit from Mindera's unique testing solutions through MultiPlan’s extensive national PPO networks.

Enhancing Patient Care and Access

Effective immediately, health plan members who are part of MultiPlan’s PHCS and MultiPlan Networks will gain direct access to Mindera Health's advanced laboratory located in Vista, CA. The lab specializes in the proprietary Mind.Px™ test, which uses innovative technology to provide precision-guided treatment options for psoriasis, a condition affecting millions in the United States.

Ron Rocca, CEO of Mindera Health, expressed enthusiasm about the collaboration, noting, "Our vision is to realize the clinical and economic benefits of precision guided biologic class selection by enabling the broadest access to our testing for psoriasis patients and the providers that are charged with caring for them. Working alongside MultiPlan opens many doors in our quest to enhance patient outcomes and streamline care pathways for those suffering from this chronic condition."

Understanding the Impact of Psoriasis

Psoriasis is not just a skin condition; it impacts over three percent of the U.S. population, leading to more than $110 billion in healthcare costs each year. The rising expenditure on specialty drugs for the treatment of psoriasis highlights the financial strain on both patients and insurance providers. With treatment response rates hovering around 52 percent, there is significant room for improvement through targeted testing and personalized treatment plans.

Cost-Effective Solutions for Healthcare Providers

In response to these challenges, Mindera's Mind.Px™ test offers a pioneering approach, enabling healthcare providers to identify the most effective treatment options before initiating medication. This predictive capacity can potentially save between $5,138 to $13,141 annually per patient by reducing the trial-and-error approach currently prevalent in psoriasis treatment. Such an evolution in patient care not only enhances efficacy but also mitigates unnecessary healthcare expenditures.

About Mindera Health

Mindera Health is an innovative company dedicated to revolutionizing skin analytics at the molecular level. Based in the San Diego area, they leverage cutting-edge technology, including dermal biomarker patches and advanced computational methods, to generate clinically validated data. As a CLIA- and CAP-certified laboratory, Mindera Health is committed to maintaining high standards in healthcare and has also achieved ISO 13485:2016 certification, ensuring the reliability of its services.

A Closer Look at the Mind.Px™ Test

The Mind.Px™ test represents a significant leap forward in the predictive analysis of treatment responses for psoriasis. Utilizing a non-invasive dermal biomarker patch, this breakthrough test can extract mRNA from the skin, which is then analyzed through sophisticated transcriptomic techniques. Clinicians can leverage this data to make informed decisions, significantly streamlining the treatment process and improving patient care.

MultiPlan's Role in Healthcare Affordability

MultiPlan stands at the forefront of addressing the escalating costs in healthcare. By fostering transparency and fairness across the healthcare system, MultiPlan is dedicated to uncovering medical savings and ensuring more affordable healthcare solutions for all stakeholders involved, from patients to providers. Their innovative approach has already made a positive impact on over 700 healthcare payors and more than 60 million consumers nationwide.

Frequently Asked Questions

What does the partnership between Mindera Health and MultiPlan entail?

The partnership allows MultiPlan’s network members access to Mindera Health’s proprietary Mind.Px™ test, enhancing patient treatment options for psoriasis.

How does Mind.Px™ improve psoriasis treatment?

Mind.Px™ provides actionable results that help physicians match patients with the most effective drug class, reducing unnecessary treatment trials.

Why is psoriasis a significant concern in healthcare?

Psoriasis affects millions and incurs substantial healthcare costs, making it crucial to find more effective and economical treatment solutions.

What certifications does Mindera Health hold?

Mindera Health is a CLIA- and CAP-certified laboratory and has received ISO 13485:2016 certification, highlighting its commitment to quality healthcare services.

What impact does MultiPlan aim to have on healthcare costs?

MultiPlan seeks to lower healthcare expenses for consumers by identifying savings opportunities and reducing instances of balance billing.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

IVD Reagents Market Growth Expected to Reach $55.3 Billion

Updated Category News Views 120

Growth Forecast for the IVD Reagents Market The global In Vitro Diagnostic (IVD) reagents market is on an impressive trajectory to reach nearly USD 55.3 billion by 2029. The demand for IVD reagents has surged, driven by numerous factors such as a rising prevalence of chronic and infectious diseases, alongside a growing emphasis on preventive healthcare. In 2022, the IVD...

Continue Reading
Cayuga Centers Expands Leadership Team with New Appointments

Updated Category News Views 235

Exciting Growth at Cayuga Centers With New Board Members Cayuga Centers is thrilled to announce the welcoming of nine new members to its Board of Trustees. This addition of distinguished professionals promises to enhance the agency's leadership and the resources it employs to support children, youth, and families across the nation. Each of these new board members brings a...

Continue Reading
Elements Massage Celebrates Skin Care Awareness Month with Tips

Updated Category News Views 204

Elements Massage Celebrates National Skin Care Awareness Month As National Skin Care Awareness Month comes to an end, Elements Massage, the nation's leading massage therapy concept, is highlighting skincare and wellness. Innovative Skincare Services Elements Massage has introduced enhanced skincare services in collaboration with Sanitas Skincare. This partnership marks...

Continue Reading
The Growth Journey of Danaher Stock Over the Past Decade

Updated Category News Views 106

Understanding Danaher's Stock Growth Danaher Corporation (NYSE: DHR) has consistently demonstrated robust performance in the stock market. With an average annual return of 13.82%, it has outpaced the market by 1.08% over the past decade. Currently, Danaher boasts a commendable market capitalization of $163.05 billion. Investment Insight: What If You Invested $100? Let’s...

Continue Reading
Matthew A. Cartwright Returns to Munley Law to Elevate Advocacy

Updated Category News Views 197

Matthew A. Cartwright Rejoins Munley Law as Of Counsel The six-term Congressman brings decades of legal expertise and legislative accomplishments back to the Pennsylvania personal injury law firm. MUNLEY Law is excited to announce the return of former U.S. Representative Matthew A. Cartwright as Of Counsel. Following a commendable 12 years in Congress, Cartwright brings a...

Continue Reading